RXDX
Ignyta, Inc.
A precision-oncology biotech that developed drugs targeting the genetic mutations driving certain cancers, most notably entrectinib, a medicine for tumors that carry NTRK and ROS1 gene fusions. Founded in San Diego, Ignyta took its name from the word "ignite," reflecting its mission to spark new cancer treatments, and it was later acquired by the Swiss pharma giant Roche. A playful detail: entrectinib was also studied as a treatment for the rare cancer behind some childhood brain tumors, showing how this small startup punched well above its weight in niche, genetically defined cancers.
CUSIP: 451731103HealthcareUS1 holder